Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK1 protein; DNMT3A protein affects the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of MAPK1 protein modified form]; EGFR mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; MUC1 mutant form inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK1 protein; AG 1879 inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of MAPK1 protein]; Cadmium Chloride promotes the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; cyanidin-3-O-beta-glucopyranoside inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Cadmium Chloride promotes the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased phosphorylation of and results in increased activity of MAPK1 protein]]